行情

PLX

PLX

PROTALIX生物疗法
AMEX

实时行情|Nasdaq Last Sale

3.800
+0.010
+0.26%
盘后: 3.860 +0.06 +1.58% 17:13 01/24 EST
开盘
3.760
昨收
3.790
最高
3.906
最低
3.760
成交量
5.73万
成交额
--
52周最高
6.00
52周最低
1.700
市值
5,638.53万
市盈率(TTM)
-0.2349
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PLX 新闻

  • 英国"脱欧"事务大臣:英国下个月将制定欧盟贸易目标
  • 新浪美股.2小时前
  • 离开武汉的500多万人都去了哪里?大数据告诉你
  • 第一财经日报.2小时前
  • iPhone12仅有5G一个卖点?销量难以回暖
  • 新浪财经-自媒体综合.3小时前
  • 确诊3例后 法国华人社区取消多场春节活动
  • 观察者网.4小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

PLX 简况

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
展开

Webull提供Protalix Biotherapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。